Patents by Inventor Mark Stephen Plummer

Mark Stephen Plummer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210017205
    Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O?M+), —P(O)(O?M+)2 and —P(O)(O?)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Applicant: Pfizer Inc.
    Inventors: Tamim Fehme Braish, Matthew Frank Brown, Ye Che, Richard Andrew Ewin, Timothy Allan Johnson, Michael Joseph Melnick, Justin Ian Montgomery, Mark Stephen Plummer, Loren Michael Price, Usa Reilly, Daniel Uccello
  • Patent number: 8779148
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: July 15, 2014
    Assignee: Pfizer Inc.
    Inventors: Usa Reilly, Michael Joseph Melnick, Matthew Frank Brown, Mark Stephen Plummer, Justin Ian Montgomery, Ye Che, Loren Michael Price
  • Publication number: 20140057919
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: Pfizer Inc.
    Inventors: Usa Reilly, Michael Joseph Melnick, Matthew Frank Brown, Mark Stephen Plummer, Justin Ian Montgomery, Ye Che, Loren Michael Price
  • Publication number: 20090227587
    Abstract: The present invention provides pyrimidines of Formula I: wherein R4, R6, and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Application
    Filed: October 19, 2004
    Publication date: September 10, 2009
    Inventors: Michael Kevin Connolly, Rocco Dean Gogliotti, Mark Stephen Plummer, Melean Visnick
  • Patent number: 7388023
    Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: June 17, 2008
    Assignee: Warner-Lambert Company LLC
    Inventors: Peter Garth Blazecka, Joseph Richard Bozelak, Norman Lloyd Colbry, Timothy Thomas Curran, Annise Paige Goodman, Kevin E. Henegar, Garrett Hoge, Paul D. Johnson, Augustine Tobi Osuma, Mark Stephen Plummer, Jacob Bradley Schwarz, Derek Clinton Vrieze, Ji Zhang
  • Patent number: 7273877
    Abstract: The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: September 25, 2007
    Assignee: Warner-Lambert Company, LLC
    Inventors: Shannon Leigh Black, Michael David Kaufman, Daniel Fred Ortwine, Mark Stephen Plummer, John Quin, III, Gordon William Rewcastle, Aurash B. Shahripour, Julie Ann Spicer, Christopher Emil Whitehead
  • Patent number: 7179934
    Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: February 20, 2007
    Assignee: Warner-Lambert Company LLC
    Inventors: Peter Garth Blazecka, Joseph Richard Bozelak, Norman Lloyd Colbry, Timothy Thomas Curran, Annise Paige Goodman, Kevin E. Henegar, Garrett Hoge, Paul D. Johnson, Augustine Tobi Osuma, Mark Stephen Plummer, Jacob Bradley Schwarz, Derek Clinton Vrieze, Ji Zhang
  • Patent number: 6875765
    Abstract: The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1? converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: April 5, 2005
    Assignee: Warner-Lambert Company
    Inventors: James Knobelsdorf, Sheryl Hays, Charles J. Stankovic, Kimberly S. Para, Michael K. Connolly, Paul Galatsis, William Harter, Aurash B. Shahripour, Mark Stephen Plummer, Beth Lunney, Bernd Janssen, Jay Bradford Fell
  • Publication number: 20040259926
    Abstract: The present invention provides benzo[b]thiophenes of Formula I: 1
    Type: Application
    Filed: June 3, 2004
    Publication date: December 23, 2004
    Inventors: Michelle M. Bruendl, Michael Connolly, Annise Paige Goodman, Rocco Dean Gogliotti, Helen Tsenwhei Lee, Mark Stephen Plummer, Karen Elaine Sexton, Aurash B. Shahripour, Greg Reichard, Melean Visnick, Michael William Wilson
  • Publication number: 20030096826
    Abstract: Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1&bgr; converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.
    Type: Application
    Filed: May 10, 2002
    Publication date: May 22, 2003
    Inventors: James Knobelsdorf, Sheryl Hays, Charles J. Stankovic, Kimberly S. Para, Michael K. Connolly, Paul Galatsis, William Harter, Aurash B. Shahripour, Mark Stephen Plummer, Beth Lunney, Bernd Janssen, Jay Bradford Fell
  • Patent number: 6083981
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula I, II, or III. ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Elizabeth Ann Lunney, Mark Stephen Plummer, Tomi Sawyer, Aurash Shahripour, Nigel Walker
  • Patent number: 6017916
    Abstract: Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: January 25, 2000
    Assignee: Warner-Lambert Company
    Inventors: Kent Alan Berryman, Annette Marian Doherty, Jeremy John Edmunds, William Chester Patt, Mark Stephen Plummer, Joseph Thomas Repine
  • Patent number: 5691373
    Abstract: Novel nonpeptide antagonists of endothelin I are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prosthatic hyperplasia (BPH), and diabetes.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 25, 1997
    Assignee: Warner-Lambert Company
    Inventors: Kent Alan Berryman, Annette Marian Doherty, Jeremy John Edmunds, William Chester Patt, Mark Stephen Plummer, Joseph Thomas Repine